Analysis of Amgen Inc.’s Q2 2026 10-Q
Filing dated 4 August 2026 for the quarter ended 30 June 2026
Where the filing and the story diverge
Amgen’s Q2 GAAP EPS rose 65% to $4.37, but non-GAAP EPS rose only 4% to $6.29: most of the GAAP jump came from lower amortisation of acquired assets, and the core non-GAAP margin slipped. The 10-Q also shows two regulatory processes opening at once, an FDA request to withdraw TAVNEOS and a partial clinical hold on subcutaneous BLINCYTO, and $5.4B of debt due within a year while cash builds and buybacks paused.
- Three findings: GAAP EPS rose 65%, core earnings rose 4%; An FDA withdrawal request for TAVNEOS and a partial hold on subcutaneous BLINCYTO; $5.4B of debt due within a year as cash builds and buybacks pause. Each is set out below with the figure, where it sits in the filing and what would close it.
- What it does not show. Nothing here shows a misstatement.
- Q2 revenue
- $10,054M, up 10%
- GAAP diluted EPS
- $4.37, up 65%
- Non-GAAP EPS
- $6.29, up 4%
- Cash
- $13,989M
- Total debt
- $57,304M
Area by area: what is solid and what is stretched
Amgen’s cash generation and receivables are healthy. The risk sits in how much the GAAP headline flatters core profit, in regulatory processes, in biosimilar erosion and in a 2026 debt maturity cluster.
Three findings, ranked by importance
Each is set out in full below: what the filing shows, the numbers, the evidence and what would close it.
GAAP EPS rose 65%, core earnings rose 4%
Lower amortisation of acquired intangibles cut cost of sales from 34.3% to 29.5% of product sales, lifting GAAP profit. On the non-GAAP measure, operating margin slipped to 48.4% from 48.9%.
Q2 GAAP diluted EPS was $4.37 against $2.65 a year earlier, while non-GAAP EPS was $6.29 against $6.02. Management attributes the gap to lower amortisation of acquisition-related assets, partly offset by higher profit share, manufacturing costs and mix. Six-month depreciation and amortisation fell $500M to $2,228M, and intangibles fell to $20,487M. The cash side is healthy: six-month operating cash flow was $6,191M, 1.48 times net income. The point is not a problem with cash but that the GAAP headline overstates the change in underlying profitability.
The earnings release reconciles GAAP to non-GAAP; the 10-Q cash flow statement shows the amortisation decline.
An FDA withdrawal request for TAVNEOS and a partial hold on subcutaneous BLINCYTO
The FDA asked Amgen to withdraw TAVNEOS voluntarily; Amgen requested a hearing on 1 June and submitted supporting materials on 23 July. Separately, subcutaneous BLINCYTO is on partial clinical hold, with enrolment paused in two studies.
TAVNEOS sold $143M in the US in Q2, about $572M a year at that pace (our calculation), and grew 36%. The 10-Q carries product-specific intangible tags for TAVNEOS, so a withdrawal would raise an impairment question as well as a revenue one. The subcutaneous BLINCYTO hold pauses enrolment in two studies while discussions with the FDA continue, and AMG 513 for obesity was discontinued. IRS notices covering proposed additional tax, repatriation tax and penalties are tagged in the filing, but their amounts are not shown.
Pipeline sections of the earnings release; XBRL tags in the 10-Q.
$5.4B of debt due within a year as cash builds and buybacks pause
Current debt rose to $5,445M from $4,599M. Amgen issued $3,964M of debt in the half and repaid $833M, ended June with $13,989M of cash, and bought back no shares in Q2 against a cap of up to $3.0B.
Total debt rose to $57,304M from $54,604M at year end, leaving net debt of about $43.3B (our calculation). Quarterly interest expense of $673M was about 24% of Q2 pre-tax income. Several 2026 maturities are tagged in the filing, including euro and sterling notes and a term loan due in October. With cash up $4.9B in the half, the question is whether the cash is for refinancing the 2026 cluster or for buybacks.
10-Q balance sheet and cash flow statement; debt instruments in the XBRL.
Other findings, checked and set aside
Each item was tested against the filing. None changes the lead findings above.
| Item | What the filing shows, and why it is not a lead finding |
|---|---|
| XBRL: a 2026 note tagged as a class of stock | The 2.00% notes due 2026 appear as a member on the cover page’s class-of-stock axis in the 8-K. Likely a tagging slip; flagged for checking, no wrongdoing implied. |
| XBRL: TAVNEOS-specific intangible tags | The 10-Q carries product-specific intangible tags for TAVNEOS, the first place to look for any impairment if withdrawal proceeds. |
| XBRL: discontinued fair-value hedges | Hedge-discontinuation and cross-currency swap tags sit alongside the euro and sterling 2026 maturities; to be reconciled to the derivatives note. |
| Acquisitions | No business combination in the period. |
| Growth drivers | Six drivers grew 26% and make up about 70% of product sales; 17 products annualise above $1B. |
10 disclosures moved
10-Q Q2 2026 compared with the 10-K for 31 December 2025.
| Status | Disclosure | Before | Now |
|---|---|---|---|
| Changed | Cost of sales Q2 2026 vs Q2 2025 · Earnings release | 34.3% of product sales | 29.5% of product sales |
| Changed | Prolia and XGEVA Q2 2026 vs Q2 2025 · Product sales | Growing base | −32% and −34%, biosimilars launched |
| New | Enbrel under Medicare Part D price setting From 1 January 2026 | Not in effect | Net price −22% |
| New | TAVNEOS FDA withdrawal request Hearing requested 1 June | Not present | Process open |
| New | Subcutaneous BLINCYTO partial clinical hold Pipeline | Not present | Enrolment paused in two studies |
| Removed | AMG 513 (obesity) Pipeline | In development | Discontinued |
| New | AstraZeneca collaboration, Amendment No. 10 Exhibit 10.24.7 | Not present | AMG883 added, 50/50 economics |
| Changed | Cash Balance sheet | $9,129M | $13,989M |
| Changed | Total debt Balance sheet | $54,604M | $57,304M |
| Changed | Quarterly dividend Declared March 2026 · Earnings release | Prior rate | $2.52, up 6% |
GAAP profit jumped as amortisation of acquired assets fell, while biosimilars, Medicare price setting and two regulatory processes changed the risk picture. Cash rose and buybacks paused.
5 markers for 3 November
Set before the numbers, so the read can be checked afterwards.
| Marker | Now | Gap widens if | Gap closes if | Result |
|---|---|---|---|---|
| Core margin | Non-GAAP operating margin 48.4%, down 0.5 points | Non-GAAP margin falls below 48% while GAAP keeps rising | Non-GAAP margin holds near 48% | Awaiting |
| Prolia and XGEVA erosion | −32% and −34% in Q2 | Declines steepen beyond Q2’s pace | Declines stabilise | Awaiting |
| TAVNEOS | $143M US sales in Q2; hearing requested | Withdrawal proceeds, or an impairment of the TAVNEOS intangible | The hearing resolves with the product on the market | Awaiting |
| Cash conversion | Six-month OCF 1.48x net income | Falls below 1.3x | Holds at 1.3x or above | Awaiting |
| Full-year guidance | Revenue $38.2B to $39.4B; non-GAAP EPS $22.30 to $23.50 | Guidance is cut | Guidance is held or raised | Awaiting |
These are monitoring checks set before the numbers, not forecasts of a loss or breach.
6 questions, checked against the call
Raised by the 10-Q. To be tested again at Q3 results on 3 November.
What this does and does not show
Biosimilars are eroding Prolia and XGEVA
Prolia sales fell 32% (volume −20%, net price −12%) and XGEVA 34% (volume −22%, net price −8%), with more biosimilars expected. Enbrel’s net price fell 22% under Medicare Part D price setting and 340B mix.
Not tested on a call in this read.
What would resolve this: The rate of decline stops steepening.
Growth products carrying the portfolio
Six growth drivers rose 26% and make up about 70% of product sales; 17 products are annualising above $1B, led by Repatha, EVENITY and UPLIZNA.
Not tested on a call in this read.
What would resolve this: Driver growth holds as the base gets larger.
AstraZeneca collaboration amended
Amendment No. 10 adds AMG883 with 50/50 sharing of development costs and net revenue; development leadership passes to AstraZeneca before the first Phase 3.
Not tested on a call in this read.
What would resolve this: Programme costs and timing are disclosed.
Nothing here shows a misstatement.
Cash flow is strong, receivables grew more slowly than sales, and the GAAP gain is explained by amortisation.
- Non-GAAP margin holds near 48%
- The TAVNEOS hearing ends with the product on the market
- Biosimilar erosion stabilises
- The 2026 maturities are refinanced without more net debt
- Core margin keeps slipping while GAAP rises
- TAVNEOS is withdrawn or its intangible impaired
- Prolia and XGEVA declines steepen
- Net debt rises with no refinancing plan
Every figure ties back to the filing
| Amgen Form 10-Q, quarter ended 30 June 2026 | Open ↗ |
| Q2 2026 earnings release, 4 August 2026 | Open ↗ |
| Exhibit 10.24.7, AstraZeneca Amendment No. 10 | Filed with the SEC |
Helmledgers reads the full filing, including the notes, and ties every figure to the statement or note it comes from, with each number re-checked against the source before release. This is an accounting read of public SEC filings, not an audit opinion and not investment advice.
- Severity
- High: material effect on cash, debt or reported results. Medium: worth tracking, smaller or less certain effect.
- On the call
- Direct answer, Partly answered (topic addressed, figure missing), Sidestepped (raised but not answered) or Not asked.
- Since the read
- Confirmed by a later disclosure, Escalated (grown since), Open (untested) or Missed (not flagged by the read).
- Said versus done
- Kept, Slipped (late), Changed (plan or terms changed), Missed or Reversed.
- Markers
- Measurable checks set before results, each with what would widen or close the gap. Scored after the next results.
- Closes if
- The evidence that would resolve a finding.
Helmledgers and its analysts hold no position in Amgen (AMGN) securities.
This is an accounting read of public SEC filings. It is not an audit opinion and not investment advice.